Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · IEX Real-Time Price · USD
1.440
0.00 (0.00%)
At close: Jul 26, 2024, 4:00 PM
1.470
+0.030 (2.08%)
After-hours: Jul 26, 2024, 7:53 PM EDT
Eyenovia Revenue
Eyenovia had revenue of $4.99K in the quarter ending March 31, 2024. This brings the company's revenue in the last twelve months to $8.78K. In the year 2023, Eyenovia had annual revenue of $3.79K.
Revenue (ttm)
$8.78K
Revenue Growth
n/a
P/S Ratio
10,077.79
Revenue / Employee
$154
Employees
57
Market Cap
88.48M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEYEN News
- 4 days ago - Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease - GlobeNewsWire
- 26 days ago - NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities - Business Wire
- 4 weeks ago - Eyenovia Announces Pricing of $5M Registered Direct Offering - GlobeNewsWire
- 2 months ago - Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol - GlobeNewsWire
- 2 months ago - Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th - GlobeNewsWire
- 3 months ago - Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension - GlobeNewsWire
- 3 months ago - Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities - GlobeNewsWire
- 4 months ago - Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings - GlobeNewsWire